The prime time for management of hepatocellular carcinoma in Hong Kong.
作者信息
Chan Landon L, Chan Stephen L
机构信息
Department of Clinical Oncology, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China.
State Key Laboratory of Translational Oncology, Sir YK Pao Centre for Cancer, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Hong Kong, China.
出版信息
Clin Mol Hepatol. 2023 Apr;29(2):345-348. doi: 10.3350/cmh.2023.0094. Epub 2023 Mar 9.
Abstract
摘要
相似文献
1
The prime time for management of hepatocellular carcinoma in Hong Kong.
Clin Mol Hepatol. 2023 Apr;29(2):345-348. doi: 10.3350/cmh.2023.0094. Epub 2023 Mar 9.
2
Transarterial chemoembolization and sorafenib in patients with intermediate-stage hepatocellular carcinoma: time to enter routine clinical practice?
Future Oncol. 2015;11(17):2371-3. doi: 10.2217/FON.15.173. Epub 2015 Aug 13.
3
Is lenvatinib in combination with transarterial chemoembolization benefit for unresectable hepatocellular carcinoma (uHCC)? The age interference needs to be eliminated.
Hepatol Int. 2024 Apr;18(2):704-705. doi: 10.1007/s12072-023-10611-z. Epub 2023 Nov 9.
4
Sorafenib in combination with transarterial chemoembolization for the treatment of hepatocellular carcinoma.
Clin Adv Hematol Oncol. 2016 Aug;14(8):585-7.
5
Treatment of intermediate-stage hepatocellular carcinoma.
Clin Adv Hematol Oncol. 2015 Aug;13(8):501-3.
6
Liver transplantation for advanced hepatocellular carcinoma after downstaging with consequential lenvatinib, transcatheter arterial chemoembolization and camrelizumab.
Br J Surg. 2024 Mar 2;111(3). doi: 10.1093/bjs/znae048.
7
Clinical practice guidelines and real-life practice on hepatocellular carcinoma: the Hong Kong perspective.
Clin Mol Hepatol. 2023 Apr;29(2):217-229. doi: 10.3350/cmh.2022.0399. Epub 2022 Dec 28.
8
[Resection or interventional treatment of hepatocellular carcinoma: which method for which patient?].
Dtsch Med Wochenschr. 2013 Sep;138(36):1780-4. doi: 10.1055/s-0033-1343347. Epub 2013 Aug 13.
9
Impact of Early Lenvatinib Administration on Survival in Patients with Intermediate-Stage Hepatocellular Carcinoma: A Multicenter, Inverse Probability Weighting Analysis.
Oncology. 2021;99(8):518-527. doi: 10.1159/000515896. Epub 2021 Apr 27.
10
Multicentric Assessment of the Hong Kong Liver Cancer Staging System in Chinese Patients Following Transarterial Chemoembolization.
Cardiovasc Intervent Radiol. 2018 Dec;41(12):1867-1876. doi: 10.1007/s00270-018-2023-z. Epub 2018 Aug 2.
本文引用的文献
1
Systemic therapy in advanced hepatocellular carcinoma.
Clin Mol Hepatol. 2023 Apr;29(2):516-519. doi: 10.3350/cmh.2023.0051. Epub 2023 Feb 20.
2
Clinical practice guidelines and real-life practice on hepatocellular carcinoma: the Hong Kong perspective.
Clin Mol Hepatol. 2023 Apr;29(2):217-229. doi: 10.3350/cmh.2022.0399. Epub 2022 Dec 28.
3
Impact of nationwide hepatocellular carcinoma surveillance on the prognosis in patients with chronic liver disease.
Clin Mol Hepatol. 2022 Oct;28(4):851-863. doi: 10.3350/cmh.2022.0037. Epub 2022 Jun 3.
4
Blood-based biomarkers for hepatocellular carcinoma screening: Approaching the end of the ultrasound era?
J Hepatol. 2023 Jan;78(1):207-216. doi: 10.1016/j.jhep.2022.08.036. Epub 2022 Sep 8.
5
Breast Cancer in Asia: Incidence, Mortality, Early Detection, Mammography Programs, and Risk-Based Screening Initiatives.
Cancers (Basel). 2022 Aug 30;14(17):4218. doi: 10.3390/cancers14174218.
6
Surveillance for hepatocellular carcinoma: It is time to move forward.
Clin Mol Hepatol. 2022 Oct;28(4):810-813. doi: 10.3350/cmh.2022.0257. Epub 2022 Sep 6.
7
Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH).
J Clin Oncol. 2023 Jan 1;41(1):117-127. doi: 10.1200/JCO.22.00392. Epub 2022 Aug 3.
8
Personalized treatment for hepatocellular carcinoma: Current status and future perspectives.
J Gastroenterol Hepatol. 2022 Jul;37(7):1197-1206. doi: 10.1111/jgh.15889. Epub 2022 May 25.
9
Current and future colorectal cancer screening strategies.
Nat Rev Gastroenterol Hepatol. 2022 Aug;19(8):521-531. doi: 10.1038/s41575-022-00612-y. Epub 2022 May 3.
10
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.
J Hepatol. 2022 Apr;76(4):862-873. doi: 10.1016/j.jhep.2021.11.030. Epub 2021 Dec 11.
Zotero 插件